Loading…
Shree Ganesh Remedies (BSE 540737)₹672.35−1.06%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Shree Ganesh Remedies reported sales of ₹23.25 Cr, down 23.2% from Sep 2025, and net profit of ₹1.64 Cr, down 67.0% year on year. For the year to Mar 2026, sales were ₹109 Cr and net profit ₹18.06 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 37.23 | 24.71 | 32.28 | 26.99 | 24.39 | 24.63 | 30.26 | 21.05 | 33.13 | 14.34 | 23.25 |
| Expenses | 20.33 | 16.62 | 20.97 | 17.09 | 14.50 | 17.31 | 20.65 | 14.34 | 21.75 | 10.98 | 19.29 |
| Operating Profit | 16.96 | 8.15 | 11.32 | 9.92 | 9.90 | 7.32 | 9.63 | 6.75 | 11.40 | 3.36 | 3.95 |
| OPM % | 45.4% | 32.8% | 35.0% | 36.6% | 40.4% | 29.6% | 31.7% | 31.9% | 34.3% | 23.3% | 16.9% |
| Other Income | 1.31 | 0.55 | 0.18 | 0.70 | 2.28 | 0.65 | 0.70 | 0.65 | 1.03 | 0.95 | 1.40 |
| Interest | 0.16 | 0.31 | 0.45 | 0.38 | 0.96 | 0.93 | 1.02 | 0.73 | 0.89 | 0.31 | 0.57 |
| Depreciation | 1.87 | 2.03 | 2.43 | 2.71 | 2.43 | 2.43 | 2.60 | 2.68 | 2.81 | 2.45 | 2.51 |
| Profit before tax | 16.23 | 6.32 | 8.63 | 7.52 | 8.77 | 4.59 | 6.70 | 3.97 | 8.71 | 1.52 | 2.26 |
| Tax % | 22.4% | 26.7% | 25.7% | 27.8% | 24.8% | 24.9% | 26.2% | 22.3% | 28.2% | 27.4% | 28.1% |
| Net Profit | 12.64 | 4.67 | 6.43 | 5.43 | 6.61 | 3.46 | 4.97 | 3.10 | 6.29 | 1.13 | 1.64 |
| EPS (Rs) | 10.39 | 3.61 | 4.98 | 4.21 | 5.12 | 2.68 | 3.85 | 2.40 | 4.87 | 0.86 | 1.26 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 34.95 | 63.89 | 48.85 | 126 | 109 | 109 | 91.77 |
| Expenses | 25.92 | 51.83 | 34.89 | 83.74 | 68.76 | 73.75 | 66.36 |
| Operating Profit | 9.01 | 13.03 | 14.03 | 42.06 | 39.08 | 35.07 | 25.46 |
| OPM % | 25.0% | 20.0% | 28.0% | 33.0% | 36.0% | 32.0% | 27.7% |
| Other Income | 0.99 | 3.99 | 2.01 | 2.99 | 3.99 | 3.01 | 4.03 |
| Interest | 0.00 | 1.01 | 0.00 | 1.01 | 1.99 | 4.01 | 2.50 |
| Depreciation | 1.01 | 2.01 | 3.01 | 6.02 | 10.03 | 10.02 | 10.45 |
| Profit before tax | 8.99 | 13.99 | 12.99 | 37.95 | 30.99 | 23.98 | 16.46 |
| Tax % | 27.9% | 23.0% | 24.9% | 25.9% | 26.0% | 25.9% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.12 | 0.61 | 1.19 | — |
| Net Profit | 6.02 | 10.03 | 10.02 | 28.10 | 23.08 | 18.06 | 12.16 |
| EPS (Rs) | 5.19 | 8.71 | 8.05 | 23.20 | 17.95 | 13.82 | 9.39 |
| Dividend payout % | 17.9% | 13.0% | 18.0% | 2.0% | 0.0% | 0.0% | — |
| Mar 2019 | Mar 2020 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 8.99 | 8.99 | 13.00 | 13.00 | 12.99 |
| Reserves | 24.95 | 32.90 | 109 | 132 | 150 |
| Borrowings | 0.99 | 3.99 | 36.00 | 38.03 | 31.01 |
| Other Liabilities | 7.04 | 9.05 | 12.06 | 8.04 | 14.06 |
| Total Liabilities | 40.97 | 54.93 | 171 | 192 | 208 |
| Fixed Assets | 14.01 | 20.01 | 81.10 | 95.16 | 105 |
| CWIP | 0.00 | 0.00 | 17.03 | 9.01 | 13.01 |
| Investments | 3.99 | 2.99 | 4.98 | 17.93 | 12.95 |
| Other Assets | 22.97 | 31.93 | 68.87 | 69.86 | 77.81 |
| Inventories | 6.49 | 6.39 | 24.91 | 21.95 | 23.94 |
| Trade receivables | 9.74 | 17.83 | 20.37 | 22.32 | 32.61 |
| Cash & equivalents | 0.99 | 2.32 | 16.23 | 10.01 | 13.46 |
| Total Assets | 40.97 | 54.93 | 171 | 192 | 208 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | −4.99 | 4.99 | 2.99 | 29.92 | 30.93 | 23.94 |
| Cash from investing activity | 0.00 | −3.01 | −1.01 | −33.09 | −35.10 | −9.03 |
| Cash from financing activity | 0.00 | 0.00 | −0.99 | 9.99 | −0.99 | −11.98 |
| Net cash flow | −5.01 | 1.01 | 2.01 | 7.02 | −6.02 | 3.01 |
| Capex | 0.11 | 0.05 | 0.02 | 31.23 | 23.24 | 16.64 |
| Free cash flow | −5.01 | 5.01 | 3.01 | −1.01 | 7.01 | 7.01 |
| CFO / OP % | −60.1% | 37.0% | 24.0% | 92.0% | 103.9% | 82.0% |
| Mar 2019 | Mar 2020 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 102 | 102 | 60 | 76 | 110 |
| Inventory days | 125 | 61 | 156 | 223 | 209 |
| Days payable | 75 | 43 | 51 | 61 | 82 |
| Cash conversion cycle | 152 | 120 | 165 | 239 | 237 |
| Working capital days | 145 | 103 | 89 | 111 | 128 |
| ROCE % | — | 34.9% | — | 18.9% | 13.9% |
For the Sep 2026 quarter, Shree Ganesh Remedies reported sales of ₹23.25 Cr, down 23.2% year on year and net profit of ₹1.64 Cr, down 67.0% year on year. The operating margin was 16.9%.
Shree Ganesh Remedies' sales for the year to Mar 2026 were ₹109 Cr; over the last twelve months they were ₹91.77 Cr.
Net profit for the year to Mar 2026 was ₹18.06 Cr, and ₹12.16 Cr over the last twelve months. Earnings per share over the same trailing period were ₹9.39.
Shree Ganesh Remedies reported borrowings of ₹31.01 Cr at Mar 2026, against cash and equivalents of ₹13.46 Cr.
Cash from operations was ₹23.94 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹7.01 Cr.